Nano-NucleOTAC-mediated Z-DNA transformation disrupts mycobacterium tuberculosis biofilms and activates antibacterial immunity
The biofilms of Mycobacterium Tuberculosis (Mtb) use extracellular DNA (eDNA) as a protective structural scaffold that shields resident bacteria from host immunity and antibiotics, promoting persistent infection. An FDA-approved DNase can partially hydrolyze eDNA but has limited affinity and nucleolytic activity against Z-form DNA (Z-DNA). After confirming the abundance of Z-DNA in Mtb biofilms, we develop Nano-NucleOTAC, a nano-nucleolysis targeting chimera that combines an eDNA-binding ligand (lactoferrin), a DNA intercalator (chloroquine) and DNase. Nano-NucleOTAC anchors to Z-DNA in Mtb H37Ra biofilms, enabling effective biofilm degradation via Z-DNA transformation and enzymatic cleavage. Following treatment, dispersed Mtb H37Ra clusters induce neutrophil extracellular trap (NET) formation and cytokine secretion (TNF, IL-1β, and IL-10) to recruit macrophages, while NET remodeling and nucleolysis enhance macrophage bactericidal effect vs. DNase alone. In mouse lung infection models, Nano-NucleOTAC improves lung drug retention, reduces pathology, and reactivates host immune responses. It also demonstrates high efficacy against Mtb strains of varying virulence (H37Ra, H37Rv) and non-tuberculous mycobacteria (Mycobacterium smegmatis). In clinical sputum samples, Nano-NucleOTAC potentiates rifampicin efficacy, and enhances neutrophil and macrophage antibacterial immunity in bronchoalveolar lavage fluid (BALF) and pus. This safe, versatile nucleic-acid-targeting strategy modulates bacterial biophysical barriers and host immunity to address biofilm-associated multidrug-resistant infections. Extracellular DNA (eDNA) from tuberculosis can protect bacteria from host immune responses and antibiotics and can contain Z form eDNA which is harder for DNase to hydrolyze. Here the authors use a nanoparticle system to more specifically target eDNA and the Z form and show cleavage of Z-DNA and improvement of immune responses against TB infection in mice.
Authors
- Pengqi Zhang (ORCID: https://orcid.org/0000-0001-8016-6307)
- Pengfei Zhao (ORCID: https://orcid.org/0000-0003-2034-7696)
- Senlin Shen
- Mingbin Zheng (ORCID: https://orcid.org/0000-0003-0463-7968)
- Zhuojun He (ORCID: https://orcid.org/0009-0002-9436-3154)
- Tetsuya Asakawa (ORCID: https://orcid.org/0000-0002-2300-3509)
- Guiqin Dai (ORCID: https://orcid.org/0000-0002-7717-7440)
- Yao Zhao (ORCID: https://orcid.org/0000-0002-2932-2164)
- Zhiqiang Lin (ORCID: https://orcid.org/0000-0003-1834-2060)
- Dongcheng Ren (ORCID: https://orcid.org/0000-0001-5037-5271)
- Hongzhou Lu (ORCID: https://orcid.org/0000-0002-8308-5534)
- Yuying Chen (ORCID: https://orcid.org/0009-0007-2192-6485)
- Xiafei Dai
- Jinzhi Pan
- Deliang Liu
- Yang Zhou
Institutions
- Guangdong Medical College (CN)
- Chinese Academy of Sciences (CN)
- Southern University of Science and Technology (CN)
- Songshan Lake Materials Laboratory (CN)
- Shenzhen Institutes of Advanced Technology (CN)
- Shenzhen Third People’s Hospital (CN)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-09-17
- DOI
- https://doi.org/10.1038/s41467-026-77825-1
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Shenzhen University